THINK INDIA JOURNAL

ISSN:0971-1260
Vol-22-Issue-37-December -2019

Role of immune cells and Inflammatory Biomarkers in atherosclerosis

AmandeepKaur
Department of Medical Laboratory Sciences, Lovely Professional University, Punjab

#Corresponding Author
Ms. AmandeepKaur
Assistant Professor
Department of Medical laboratory sciences
School of Physiotherapy and Paramedical Sciences
Lovely Professional University, Phagwara, Punjab-144411, India
E-mail: amandeep.24931@lpu.co.in
Phone no.- 9915450647

Abstract:

The risk factors for coronary heart disorder, including hypercholesterolemia, high blood pressure, smoking, diabetes mellitus, and diet rich in fats all have been related with injuries in endothelial function. Decreasedfunctions of endothelium may encourage the growth of atherosclerosis over its effects on vaso-regulation, adhesion of platelet and monocyte, growth of vascular smooth muscle cell, and also clotting. Amplified oxidative stress might be alternativetool through which endothelial dysfunction leads to atherosclerosis.Modifications of risk factors, particularly depressing high concentrations of low-density lipoprotein cholesterol, improvefunctions of endothelial. Several studies showedconfirmed better endothelial working byreducing levels of cholesterol in patients with evidentlyraised or marginalraises in concentration of cholesterol. The part of various vascular adhesion particles in growth as well asadvancement of atherosclerosis is also reported. This review highlighted the role of Macrophages/ monocytes, platelets, T cells, B cells, leukocytes, some vascular adhesion molecules which includes selectins, vascular cell adhesion molecules (VCAM)-1, inter-cellular adhesion molecule1 (ICAM-1) and various inflammatory biomarkersin atherosclerosis.

Keywords: *Atherosclerosis, Low-Density lipoprotein(LDL), cardio vascular disease(CVDs), cytokines*

Introduction

Atherosclerosis a advanced chronic, worseningillness of tunica intima inside arteryconsideredthroughbuildup of lipid on the wallsprimarily detected by the formation of fatty strips in subintimal tissue causing many medically significant cardiovascular diseases(CVDs) like coronary artery disease, stroke and peripheral artery diseases.[1]Pathogenic association in between moving lipoproteins, hemodynamic factor, several endothelial cell, smooth muscle cells, various macrophages, T cells is known to participate in the construction of fatty streaks. The expansion of coronary artery disease through two main mechanics includes endothelial dysfunction or damage, and buildup and alteration of cholesterol, primary low-density

ISSN:0971-1260
Vol-22-Issue-37-December -2019

lipoprotein (LDL).[2-4]Coronary risk factors aid the atherosclerotic practice by growing LDL cholesterol concentrations, increasing endothelial permeability to LDL, and endorsing cholesterol modification which includes oxidation, glycosylation, and acetylation. Oxidized LDL cholesterol produces endothelial dysfunction. The pathophysiology of atherosclerosis includes a number of procedures which include macrophage uptake of oxidized cholesterol, discharge of growth factors, propagation of vascular smooth muscle cells, and amplification of collagen.Metabolic deviations which include sensitivity to insulin, high blood pressure, dyslipidemia and fatnesstogether referred to metabolic syndrome often also contribute to atherosclerosis.[5]Atherosclerotic abrasion formation is a multifaceted process which involves arterial endothelium, monocytes / macrophages, smooth muscle cells (SMCs) and a functional link of growth factors and cytokines.[6]An originatingincident in atherosclerosis process isbuildup of LDLs in subendothelial medium, undergoing minor changes like lipolysis, proteolysis and accumulation, in addition to oxidative shifts.[7-9]Numerous studies suggest that a potent inducer of atherogenesis is oxidized LDL (oxLDL).In addition, oxLDL induces cells of endothelial to createpro-inflammatory molecules, like adhesive particles and growth factors, results in enrolment of monocytes into the walls of blood vessels.[7]In addition to pro-inflammatory result, oxidation of LDLin both primary and advanced atherosclerotic lesions is linked with apoptosis and the appearanceof apoptosis-related proteins.[10]Monocyte recruitment along the vascular wall is aassurance in lesion of atherosclerosis.Monocyte attachment and transmigration is based on the endothelial surface's corresponding adhesion molecules, the expression of which is moderated by several chemical mediators.The atherosclerotic plaque is categorized by various macrophage population that represents the micro-environment complexity and heterogeneity to which cells are uncovered after arrivingto the wall of artery.Macrophages segregate, multiply and experience apoptosis within atherosclerotic lesions.The expansion of therapeutic strategies to aim monocytes / macrophages in the atherosclerotic plaque has become a crucialfact of attention for investigators in area, taking into account that their activity has a clear and important effect on all lesion stages.

Pathophysiology of atherosclerosis

Several studies have shown that endothelial damage or buildup of LDLsinside the wall of artery causing atherosclerosis, typically susceptible to oxidation or alteration.These altered or oxidized LDLs stimulate innate and adaptive immune responses in accordance by low-grade inflammation induced through minor endothelial harm. Such immune responses are currently recognized to show a significant role in production of athero-sclerosis. Platelets, monocytes, neutrophils, T cells along with B cells all are considered as major cell in sense of atherosclerosis.

Role of Platelets

Just 3 years ago the dominant viewpoint imagined atherosclerosis as a weak proliferative practice.[11]According to this theory, endothelial sheddingdamage resulted in platelet accumulation and discharge of platelet-derived growth factor that caused the multiplying of cells

ISSN:0971-1260
Vol-22-Issue-37-December -2019

of smooth muscle inintima layer of artery and formed the plaque of atherosclerosis nidus. Different risk factors includehyperchlestremia, hypertension, cigarette smoking and diabetied, high levels of transformed LDL's,diabeties generated free radicals,high blood pressure and smoking, inherited factors[12],high levels ofhomocysteinemia, contagions with several microorganisms including are capable to rise the amount of stimulated platelets into thecirculation.In the expansion and advancement of atherosclerosis, involvement of circulating stimulated platelets accompanying major thrombotic procedures like myocardial infarction or stroke can be important.In atherosclerosis, the molecular procedures which are responsible for platelet stimulation are not known. In thrombotic case, activation of platelet starts by binding adhesive receptors to its ligands on constituents of matrix which is extracellular.[13]This process is more enhanced by sending signals bythrombin formed upon the membrane of triggered platelets, adenosine diphosphate (ADP) created by cells like vascular cells and platelets, epinephrine secreted in response to stress, and throm-boxane (TX) A2 manfactured by trigerred platelets.[13]

Role of Monocytes/macrophages

Low-grade inflammatory endothelial injury activates modulation of cell bond molecules like molecule-1 (VCAM-1)[14], mole-cule-1 (ICAM-1) inter cellular adhesion molecules[15], and selectin.[16]Thesefragmentsassist monocytes to get adhered to endothelial cells layer. Monocytes travelbeneath endothelial layernext binding to damaged endothelial wall, and it is stated that some chemokines are associated with the same process. Example, monocyte chemoattractant protein-1 (MCP-1) excitesrelocationpluspenetration of some monocytes with receptor C C chemokine receptor-2 (CCR2).[17]It is also known that IL-8 is associated with cell migration via its CXCR2 receptor.[18]Macrophage-stimulating factor (M-CSF) differentiates monocytes into macrophages as they travel to endothelium, which is known to be one of thecritical step for atherosclerosis production.S1P receptor 3 (S1P3) also plays a causal role in atherosclerosis pathogenesis.[19]

Changed lipoproteins stimulate togetherendothelial cells plus monocytes /macrophages, results in moresubendothelial monocytesrelocation in reaction to locally created chemo-attracting molecules and cytokine such as interferon-c (IFN-c), interleukin-1b (IL-1-b), IL-6, tumor necrosis factor-a (TNF-a).[20]Macrophages, first cellular constituents in development of lesions; they absorb lipid particles over specific cell surfaces proteins, scavanger receptors (SRs), such as SR-A and CD36, which are not regulated by feedback mechanisms such as LDL receptors.This processes induce a distinctive inflammatory reaction by liberating inflammatory molecules into the extracellular environment like the protein-1 monocyte chemoattractant (MCP-1) that invite more macrophage and new cells inabrasion.[21, 22]Macrophages gatheroxLDL lipids resulting in the development of lipid-loaded foam cells.Foam cells can remove lipids also

ISSN:0971-1260
Vol-22-Issue-37-December -2019

fromsubendothelial space via ATP-binding cassette transporters like ABCA1, ABCG1 to high-density lipoprotein (HDL), but when transportation is reserved, they continuously gather lipids leading to enlarged cell loss of inflammatory cells and discharge of intracellular molecules leading to continuous chronic inflammation.[23-25]In count to altered or oxidized LDLs, multiple lines of suggestion indicate that bacterial yields likelipo polysaccharides and heat-shock proteins can lead to plaque formation by acting on vascular cells and triggering innate immunity.

Role of Neutrophils

Classically, neutrophils were known as the first protection cells during acute inflammatory responses and getslightconsideration in mechanism of atherosclerosis.Current progress in considering atherosclerosis process, however, has made neutrophils one of the utmost significant suppliers to atherosclerosis production. However, alike monocytes, various chemotactic signals, particularly chemo-kine provided by platelets which are activated, recruit neutrophils in atherosclerotic abrasions.In addition, by discharging granule proteins like azurocidin, cathepsin G, and a-defensins, neutrophils also recruit monocytes into atherosclerotic abrasions, aggravating atherosclerosis. It has also been documented that these granule proteins activate macrophages and facilitate the development of foam cells.[26]Taken together, involving neutrophils in atherosclerosis pathogenesis that extends anti-inflammatory therapeutic methods.It should be consideredthat since neutrophil is part of the first defense cells, strategies for inhibiting neutrophil role need to be wisely controlled so that no severe adverse effect can occur.

Role of T-lymphocytes

T cells, monocytes/ macrophages are among the initial cells associated with atherosclerotic plaque formation.[27]It has been reported that advanced human atherosclerotic plaques contain a huge number of T cells.Most of the T cells expresses CD3, CD4, and T cell receptor (TCR) and interrelatewith antigen-specific phagocyte like macrophages and dendritic cells (DCs).Such T cells produces cytokine and cause swelling in response to contact to the precise antigen, and some T cell (CD8 + T cells) even have method to destroy cell, thus participating to atherosclerosis growth.

Some adhesive molecules and chemokines like the interferon-γ (IFN-γ)-inducible chemokine ligands (CXCLs), IFN-γ-inducible protein-10 (IP-10), monokine induced by IFN-γ (MIG), and IFN-γ-inducible T-cell α-chemoattractant (I-TAC)[28, 29]facilitate the movement of T lymphocytes to intima through VCAM-1. Such chemokines also bind to the CXCR3 chemokine receptor, expressed in the plaque on T lymphocytes. The T lymphocytes release pro-inflammatory cytokines when stimulated in the intima, including the CD40 ligand, CD154.CD40 ligation by CD154 brings the development of extracellular matrix-degrading Matrix-metalloproteinases(MMPs) and strong tissue factor(TF) procoagulant.[30, 31]TF induces the

ISSN:0971-1260
Vol-22-Issue-37-December -2019

cascade of coagulation, increasing the level of formation of thrombus in lipid center of the plaque.

Helper T cells are classified into Th1 and Th2 subtypes that aredistinguished from CD4 + T cell and have a significant role in antigen detection.Although native cytokines and antigen presenting cells regulate the proportion of Th1 and Th2 subtype, the majority of T cells found in atherosclerotic abrasions are Th1 cells. These cellsdischarge cytokines like interferon-g (IFN-g), IL-2,tumor necrosis factor (TNF), both famous to stimulate inflammation through the use of macrophages and vascular cells. In addition, it has also been shown to encourage atherosclerosis through cytokines like IL-18 and IL-12, which activate Th1cells.Taken together, reactions to Th1 typically speed up atherosclerosis by stimulating the pathways of inflammation.

Role of B-Lymphocytes:

B lymphocytes discharge an antibody that is central part for humoral immunity. Collectingproofrecommended that humoral immunity appears to reduce other than stimulate atherosclerosis. But, the outcome of B cells on atherosclerosis is said to depend upon various subtypes of cell, commonly called B1cells and B2cells. It is imagined that B2 B cells may support atherosclerosis through their capability to yield inflammatory cytokines that can trigger Th1 T cells and monocyte/macrophages.[27]Instead, this could be due to the occurrence of immune complexes which involves IgG auto-antibodies in atherosclerotic plaques[32], or yet undiscovered tools. That B2 B cells may have atheroprotective things under various conditions was recommended by findings that adoptive transfer of 30 or 60 million splenic B2 B cells from Apoe-/- mice significantly compact Western diet-induced atherosclerosis in mMTApoe-/- mice.[33]B1 B cells instinctively produce antibodies, with few nucleotide additions, that are chieflyIgM.[34-36] Their protecting role in atherosclerosis is due to the construction of natural antibodies (NAbs) that bind altered self-epitopes like oxidation-specific epitopes (OSEs) originateon oxLDL and apoptotic cells.[37] One class of NAbs particularly called E06, binds to phosphorylcholine on oxLDL surface and apoptotic cells. It has been identified that E06 is atheroprotectivethrough both the inhibition of oxLDL uptake by occupant macrophages which slows their transformation to foam cells and amplified clearance of apoptotic bodies that decrease necrotic core development.[38] Thus it is recommended that the atherosclerosis can be stopped by inhibiting B2 cells.

Inflammatory biomarkers:

Various biomarkers are also involved in the prediction of cardio-vascular events. C-reactive protein (CRP) possibly is one of the high favorableindicators in case of vascular inflammation. CRP, an acute phase proteins, mainly produced in liver throughevents of acute inflammation or contamination. CRP is also identified at nativespots of inflammation or damage. But, the intensities of CRP formed during reaction to vascular inflammation arenormally very less. High-sensitivity CRP (hs-CRP) analyzetechniquesthusdeveloped to identify very little changes in

ISSN:0971-1260
Vol-22-Issue-37-December -2019

concentration of CRP.[39] Cytokines send signals inperspective of immunologicreactions, hematopoiesis,inflammatory reactions, and many extra basic biological purposes. For example, interleukin (IL) 6 and tumor necrosis factor (TNF) α, belongs to inflammatory cytokine family secreted by vascular smooth muscle cells, endothelial cell, monocytes/macrophages, and so onward, is revealed to be extremely participant in atherosclerosis.[39] Like hsCRP, IL-6 has been drawn attention to as a. important biomarker for expecting cardiovascular risk, because it is known to encourageproduction of CRP in liver and is categorized as an upstream cytokine to reveal inflammation. Moreover, IL-6 levels have been shown to compare with endothelial dysfunction and subclinical atherosclerosis.[40] Interleukin-1 is one of the pro inflammatory cytokine and a dominantintermediate in cytokine system. The action of IL-1 is counter regulated through its endogenous inhibitor, IL-1 receptor opponent alpha (IL-1Ra). Interleukin-1 as well as IL-1Ra isformed and released by different types of cells, which includes those cells that control immunity. IL-1 as well as IL1Ra transcripts are found on the wall of vessel, suggests that following cytokines might involve in the growth and advancement of vascular disease.[41]

Conclusion:

The suggestion indicates that mediators that harm and so increase the penetrability of the arterial endothelium layer can cause atherosclerosis. However, it may be that external mediatorsonly elicit atherosclerotic process, which then converts to self-perpetuating.The endothelium seems to be an essentialpart in the expansion of atherosclerosis over its effects on coagulation,vaso-regulation, monocyte and platelet adhesion. Coronary risk aspectslike hyper-cholesterolemia, smoking, high blood pressure, diabetes, and diet rich in fat impair endothelial function.[4]

The concise data advise a stronginput of innate immunity, like inflammatory mediators including- cytokines, chemokine, and pattern recognition molecules in atherogenesis. Higherbuildup of smooth muscle cells, monocytes/macrophages, T-cells, B-cellsalong with elevated levels of extracellular matrix constituents, results for example in higher LDL withholding or other cells, may aid as an ‘immunovascular memory’ leads to an ever-growing reaction to reiterative incursion. The growingcontact of native vessel wall cell with entering leukocytes may further boost and reinforce inflammation in the vessel wall by effectivelyadaptable local formation of cytokine.[42] This may elucidate, in part, the intensedeclines in atherosclerosisdetected with cholesterol drop, particularly declines in LDL cholesterol also by controlling the endothelium injury and inflammation.

References:

[1] G. Gresham, and A. Howard, “The histogenesis of the atherosclerotic “fatty streak”,” Journal of atherosclerosis research, vol. 1, no. 5-6, pp. 413-416. 1961.

ISSN:0971-1260
Vol-22-Issue-37-December -2019

[2] G. N. Levine, J. F. Keaney Jr, and J. A. Vita, "Cholesterol reduction in cardiovascular disease—clinical benefits and possible mechanisms," New England Journal of Medicine, vol. 332, no. 8, pp. 512-521. 1995.
[3] S. P. Glasser, A. P. Selwyn, and P. Ganz, "Atherosclerosis: risk factors and the vascular endothelium," American heart journal, vol. 131, no. 2, pp. 379-384. 1996.
[4] R. A. Vogel, "Coronary risk factors, endothelial function, and atherosclerosis: a review," Clinical cardiology, vol. 20, no. 5, pp. 426-432. 1997.
[5] H. Haller, "Epidermiology and associated risk factors of hyperlipoproteinemia," Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, vol. 32, no. 8, pp. 124-128. 1977.
[6] Z. M. Ruggeri, "Von Willebrand factor: looking back and looking forward," Thrombosis and haemostasis, vol. 98, no. 07, pp. 55-62. 2007.
[7] W. Martinet, and M. M. Kockx, "Apoptosis in atherosclerosis: focus on oxidized lipids and inflammation," Current opinion in lipidology, vol. 12, no. 5, pp. 535-541. 2001.
[8] M. Pentikäinen, K. Öörni, M. Ala-Korpela, and P. Kovanen, "Modified LDL–trigger of atherosclerosis and inflammation in the arterial intima," Journal of internal medicine, vol. 247, no. 3, pp. 359-370. 2000.
[9] K. Öörni, M. O. Pentikäinen, M. Ala-Korpela, and P. T. Kovanen, "Aggregation, fusion, and vesicle formation of modified low density lipoprotein particles: molecular mechanisms and effects on matrix interactions," Journal of lipid research, vol. 41, no. 11, pp. 1703-1714. 2000.
[10] Y. Okura, M. Brink, H. Itabe, K. J. Scheidegger, A. Kalangos, and P. Delafontaine, "Oxidized low-density lipoprotein is associated with apoptosis of vascular smooth muscle cells in human atherosclerotic plaques," Circulation, vol. 102, no. 22, pp. 2680-2686. 2000.
[11] R. Ross, "Glomset. JA. The pathogenesis of atherosclerosis," N. Engl. J. Med, vol. 295, pp. 420. 1976.
[12] K. Musunuru, and S. Kathiresan, "Surprises from genetic analyses of lipid risk factors for atherosclerosis," Circulation research, vol. 118, no. 4, pp. 579-585. 2016.
[13] P. Aukrust, J. K. Damås, and N. O. Solum, "Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation?," Journal of the American College of Cardiology, 2004.
[14] B. V. Khan, S. S. Parthasarathy, R. W. Alexander, and R. M. Medford, "Modified low density lipoprotein and its constituents augment cytokine-activated vascular cell adhesion molecule-1 gene expression in human vascular endothelial cells," The Journal of clinical investigation, vol. 95, no. 3, pp. 1262-1270. 1995.
[15] T. Nagel, N. Resnick, W. J. Atkinson, C. F. Dewey, and M. A. Gimbrone, "Shear stress selectively upregulates intercellular adhesion molecule-1 expression in cultured human vascular endothelial cells," The Journal of clinical investigation, vol. 94, no. 2, pp. 885-891. 1994.
[16] K. Ley, "The role of selectins in inflammation and disease," Trends in molecular medicine, vol. 9, no. 6, pp. 263-268. 2003.
[17] S. L. Deshmane, S. Kremlev, S. Amini, and B. E. Sawaya, "Monocyte chemoattractant protein-1 (MCP-1): an overview," Journal of interferon & cytokine research, vol. 29, no. 6, pp. 313-326. 2009.

ISSN:0971-1260
Vol-22-Issue-37-December -2019

[18] W. A. Boisvert, L. K. Curnss, and R. A. Terkeltaub, "Interleukin-8 and its receptor CXCR2 in atherosclerosis," Immunologic research, vol. 21, no. 2-3, pp. 129-137. 2000.
[19] P. Keul, S. Lucke, K. von Wnuck Lipinski, C. Bode, M. Gräler, G. Heusch, and B. Levkau, "Sphingosine-1-phosphate receptor 3 promotes recruitment of monocyte/macrophages in inflammation and atherosclerosis," Circulation research, vol. 108, no. 3, pp. 314-323. 2011.
[20] M. T. Quinn, S. Parthasarathy, L. G. Fong, and D. Steinberg, "Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis," Proceedings of the National Academy of Sciences, vol. 84, no. 9, pp. 2995-2998. 1987.
[21] D. Steinberg, "Parthasarathy 5, Carew TE, Khoo JC, Witztum JL," Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med, vol. 320, pp. 915-924. 1989.
[22] M. Navab, J. A. Berliner, A. D. Watson, S. Y. Hama, M. C. Territo, A. J. Lusis, D. M. Shih, B. J. Van Lenten, J. S. Frank, and L. L. Demer, "The yin and yang of oxidation in the development of the fatty streak: a review based on the 1994 George Lyman Duff Memorial Lecture," Arteriosclerosis, thrombosis, and vascular biology, vol. 16, no. 7, pp. 831-842. 1996.
[23] C. K. Glass, and J. L. Witztum, "Atherosclerosis: the road ahead," Cell, vol. 104, no. 4, pp. 503-516. 2001.
[24] P. Libby, P. M. Ridker, and A. Maseri, "Inflammation and atherosclerosis," Circulation, vol. 105, no. 9, pp. 1135-1143. 2002.
[25] G. K. Hansson, and P. Libby, "The immune response in atherosclerosis: a double-edged sword," Nature Reviews Immunology, vol. 6, no. 7, pp. 508. 2006.
[26] O. Soehnlein, "Multiple roles for neutrophils in atherosclerosis," Circulation research, vol. 110, no. 6, pp. 875-888. 2012.
[27] T. Kyaw, C. Tay, A. Khan, V. Dumouchel, A. Cao, K. To, M. Kehry, R. Dunn, A. Agrotis, and P. Tipping, "Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis," The Journal of Immunology, vol. 185, no. 7, pp. 4410-4419. 2010.
[28] F. Mach, A. Sauty, A. S. Iarossi, G. K. Sukhova, K. Neote, P. Libby, and A. D. Luster, "Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells," The Journal of clinical investigation, vol. 104, no. 8, pp. 1041-1050. 1999.
[29] E. A. Heller, E. Liu, A. M. Tager, Q. Yuan, A. Y. Lin, N. Ahluwalia, K. Jones, S. L. Koehn, V. M. Lok, and E. Aikawa, "Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells," Circulation, vol. 113, no. 19, pp. 2301-2312. 2006.
[30] F. o. Mach, U. Schönbeck, J.-Y. Bonnefoy, J. S. Pober, and P. Libby, "Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40: induction of collagenase, stromelysin, and tissue factor," Circulation, vol. 96, no. 2, pp. 396-399. 1997.
[31] F. Mach, U. Schönbeck, G. K. Sukhova, T. Bourcier, J.-Y. Bonnefoy, J. S. Pober, and P. Libby, "Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40–CD40 ligand signaling in

ISSN:0971-1260
Vol-22-Issue-37-December -2019

atherosclerosis," Proceedings of the National Academy of Sciences, vol. 94, no. 5, pp. 1931-1936. 1997.

[32] S. Ylä-Herttuala, W. Palinski, S. W. Butler, S. Picard, D. Steinberg, and J. L. Witztum, "Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL," Arteriosclerosis and thrombosis: a journal of vascular biology, vol. 14, no. 1, pp. 32-40. 1994.

[33] A. C. Doran, M. J. Lipinski, S. N. Oldham, J. C. Garmey, K. A. Campbell, M. D. Skaflen, A. Cutchins, D. J. Lee, D. K. Glover, and K. A. Kelly, "B-cell aortic homing and atheroprotection depend on Id3," Circulation research, vol. 110, no. 1, pp. e1-e12. 2012.

[34] C. L. Barber, E. Montecino-Rodriguez, and K. Dorshkind, "Developmental relationships between B-1 and B-2 progenitors," Taylor & Francis, 2011.

[35] C. A. Pennell, T. J. Mercolino, T. A. Grdina, L. W. Arnold, G. Haughton, and S. H. Clarke, "Biased immunoglobulin variable region gene expression by Ly-1 B cells due to clonal selection," European journal of immunology, vol. 19, no. 7, pp. 1289-1295. 1989.

[36] T. J. Mercolino, A. L. Locke, A. Afshari, D. Sasser, W. W. Travis, L. W. Arnold, and G. Haughton, "Restricted immunoglobulin variable region gene usage by normal Ly-1 (CD5+) B cells that recognize phosphatidyl choline," Journal of Experimental Medicine, vol. 169, no. 6, pp. 1869-1877. 1989.

[37] C. J. Binder, "Natural IgM antibodies against oxidation-specific epitopes," Journal of clinical immunology, vol. 30, no. 1, pp. 56-60. 2010.

[38] M.-Y. Chou, L. Fogelstrand, K. Hartvigsen, L. F. Hansen, D. Woelkers, P. X. Shaw, J. Choi, T. Perkmann, F. Bäckhed, and Y. I. Miller, "Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans," The Journal of clinical investigation, vol. 119, no. 5, pp. 1335-1349. 2009.

[39] T. Soeki, and M. Sata, "Inflammatory biomarkers and atherosclerosis," International heart journal, pp. 15-346. 2016.

[40] J. Moriya, "Critical roles of inflammation in atherosclerosis," Journal of cardiology, vol. 73, no. 1, pp. 22-27. 2019.

[41] A.-M. Kampoli, D. Tousoulis, C. Antoniades, G. Siasos, and C. Stefanadis, "Biomarkers of premature atherosclerosis," Trends in molecular medicine, vol. 15, no. 7, pp. 323-332. 2009.

[42] H. Loppnow, K. Werdan, and M. Buerke, "Invited review: Vascular cells contribute to atherosclerosis by cytokine-and innate-immunity-related inflammatory mechanisms," Innate immunity, vol. 14, no. 2, pp. 63-87. 2008.